Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Matern Child Health J ; 28(4): 767-774, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38358537

ABSTRACT

BACKGROUND: Chronic hepatitis-B virus (HBV) infection due to mother-to-child transmission (MTCT) during the perinatal period is an important global health concern. Chile is a low-prevalence country with an increasing migratory inflow from Latin- American countries, with intermediate to high endemic rates of HBV infection, and until 2021, there is no universal maternal screening. This study aimed to evaluate infant outcomes using a risk-based strategy of maternal screening to prevent MTCT of hepatitis B virus (HBV) in a low-prevalence country. METHODS: This prospective study included infants born to HBsAg-positive women detected using a local risk-based strategy. The exposed infants received immunoprophylaxis (IP) and follow-up to evaluate their clinical outcomes and immune responses through post-serological vaccine testing (PSVT) after completing the three- dose schedule of the HBV vaccine. RESULTS: A total of 99 HBsAg-positive mothers were detected. Seventy-six (82%) infants completed the follow-up and had PSVT between 9 and 12 months of age. 55.2% female, the median gestational age was 39 weeks (25-41) and the median birth weight was 3,130g (816-4,400 g). All patients received IP with recombinant HBV vaccine plus hepatitis-B virus immunoglobulin (HBIG) and three doses of the HBV vaccine. There were no cases of HBV infection, and 96% (72) responded to immunization with HBsAg antibodies (anti-HBsAg) >10 UI/ml, with a median level of 799 IU/ml. CONCLUSIONS: A high-risk strategy can be implemented in countries with non-universal screening for VHB. Timely IP plus high-uptake VHB vaccination in infants born to HBsAg-positive mothers was associated with a high immunogenic response and absence of MTCT.


Subject(s)
Hepatitis B, Chronic , Hepatitis B , Pregnancy Complications, Infectious , Pregnancy , Infant , Female , Humans , Male , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/prevention & control , Hepatitis B Surface Antigens/therapeutic use , Prevalence , Prospective Studies , Infectious Disease Transmission, Vertical/prevention & control , Hepatitis B virus , Hepatitis B/epidemiology , Hepatitis B/prevention & control , Hepatitis B Vaccines/therapeutic use , Pregnancy Complications, Infectious/prevention & control
2.
Arch Argent Pediatr ; 119(2): e117-e120, 2021 04.
Article in English, Spanish | MEDLINE | ID: mdl-33749200

ABSTRACT

Chronic hepatitis B virus infection is one of the most prevalent diseases worldwide. It may progress to cirrhosis and hepatocellular carcinoma. An early detection, not using intravenous drugs, sex education, and immunization are critical for prevention. An infection in the neonatal period and in the first year of life becomes chronic in more than 90 % of children. Vertical transmission from a mother with hepatitis B virus to the newborn infant is currently the most common mode of transmission. Detection, immunoglobulin administration, and immunization help to reduce it. Antiviral therapy may accelerate the transition from the active to the inactive phase of infection by two or three years, without affecting the recovery process. A timely treatment of some selected cases may prevent hepatitis B progression.


La infección crónica con el virus B de la hepatitis es una de las enfermedades de mayor prevalencia mundial. Puede evolucionar a la cirrosis y carcinoma hepatocelular. La detección temprana, evitar la utilización de drogas intravenosas, la educación sexual y la vacunación son fundamentales para la prevención. La infección neonatal y durante el primer año de vida evoluciona hacia la cronicidad en más del 90 % de los niños. La transmisión vertical, de una madre con virus B de la hepatitis al recién nacido, es, actualmente, la forma más frecuente de infección. Su detección y la administración de inmunoglobulinas y vacuna disminuyen esta vía de infección. El tratamiento antiviral puede acelerar en dos o tres años el pasaje de la fase activa a la inactiva de la infección, sin influir en el proceso hacia la recuperación. El tratamiento oportuno de algunos casos elegidos puede evitar la progresión de la enfermedad.


Subject(s)
Hepatitis B, Chronic , Hepatitis B , Pediatrics , Antiviral Agents/therapeutic use , Child , Hepatitis B/drug therapy , Hepatitis B/transmission , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/prevention & control , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Liver Cirrhosis
3.
Ann Hepatol ; 19(4): 388-395, 2020.
Article in English | MEDLINE | ID: mdl-32507734

ABSTRACT

INTRODUCTION AND OBJECTIVES: Universal vaccination at birth and in infancy is key to the elimination of chronic hepatitis B infection. We aimed to assess hepatitis B immune-prophylaxis and perinatal transmission knowledge, in a large and ethnically diverse cohort of previously pregnant North American women, chronically infected with hepatitis B. MATERIALS AND METHODS: The Hepatitis B Research Network (HBRN) is comprised of 28 Clinical Centers in the United States and Canada. Female cohort participants were administered a questionnaire to assess: (1) their assertion of knowledge regarding HBV prophylaxis at birth, testing, and diagnosis of hepatitis B in their children, and (2) the percentage of affirmative to negative responses for each of the HBV-related interventions her child may have received. The relationship between asserted knowledge, actions taken and maternal demographics were assessed. RESULTS: A total of 351 mothers with 627 children born in or after 1992 were included. Median age at enrollment was 39.8 years. Mothers were mostly foreign-born with the largest percentage from Asia (73.4%) and Africa (11.7%). Of the 627 children, 94.5% had mothers who asserted that they knew whether their child had received HBIG or HBV vaccine at birth, for 88.8% of the children, their mothers indicated that they knew if their child was tested for HBV and for 84.5% of children, their mothers knew if the child was diagnosed with HBV infection. Among children whose mothers asserted knowledge of their HBV management, 95.3% were reported to have received HBIG or HBV vaccine, 83.4% of children were said to have been tested for HBV, and 4.8% of children were said to have been diagnosed with HBV. Younger maternal age was the only factor significantly associated with higher percentage of children for whom mothers reported knowledge of testing (p=0.02) or diagnosis of HBV (p=0.02). CONCLUSIONS: While high percentages of North American children had mothers asserting knowledge of HBV prophylaxis and testing, knowledge gaps remain, with mothers of 5.5-15.5% of children lacking knowledge of key components of the HBV prevention and diagnosis in the perinatal setting. Targeted education of HBsAg-positive mothers may aid in closing this gap and reducing vertical transmission.


Subject(s)
Health Knowledge, Attitudes, Practice , Hepatitis B, Chronic/transmission , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious , Adult , Canada , Female , Hepatitis B Antibodies/therapeutic use , Hepatitis B Vaccines/therapeutic use , Hepatitis B, Chronic/prevention & control , Humans , Immunization, Passive , Immunologic Factors/therapeutic use , Pregnancy , United States
4.
Braz. j. infect. dis ; Braz. j. infect. dis;23(6): 419-426, Nov.-Dec. 2019. tab
Article in English | LILACS | ID: biblio-1089319

ABSTRACT

ABSTRACT Introduction: Hepatitis B virus (HBV) is responsible for one of the most common human viral infections. An estimated 257 million people are living with chronic HBV infection worldwide, and mortality has reached 900,000 deaths in recent years. In 2001, the World Health Organization reported a prevalence of chronic hepatitis B infection in Iran between 2-7%. Objective: To assess the effect of the national HBV mass vaccination program after 25 years. Methods: A retrospective cohort study was conducted in vaccinated and unvaccinated people according to the year of birth. Blood samples were obtained from each enrolled person and data about demographic variables, and medical and vaccination history were collected using a standardized questionnaire. Persons were considered uninfected if they were negative for both HBsAg and anti-HBc. Also, Vaccine effectiveness was measured by calculating the risk of disease among vaccinated and unvaccinated persons and defining the percentage risk reduction of infection in the vaccinated group. Results: A total of 2720 persons were interviewed. The rate of HBV breakthrough infection among the vaccinated group was significantly lower than in unvaccinated group. One hundred ninety-four cases with positive HBV markers of infection were identified. The risk ratio of HBV infection was 0.71, 95% CI: 0.54-0.94 (vaccinated/unvaccinated). The estimated vaccination effectiveness against Hepatitis B infection was 29% (95% CI: 6%-46%). Conclusions: Iran has successfully combined hepatitis B vaccination into regular immunization programs. The WHO goal of reducing HBsAg prevalence to an equivalent of 1% by 2020 has been reached. With respect to vaccination effectiveness and low prevalence of the disease in the country, catch-up hepatitis B vaccination programs for adolescents can guarantee the immunity of the population.


Subject(s)
Humans , Male , Adolescent , Adult , Middle Aged , Young Adult , Vaccination/statistics & numerical data , Hepatitis B Vaccines/administration & dosage , Immunization Programs/statistics & numerical data , Hepatitis B, Chronic/prevention & control , Hepatitis B/prevention & control , Prevalence , Surveys and Questionnaires , Retrospective Studies , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/epidemiology , Hepatitis B/epidemiology , Iran/epidemiology
5.
Braz J Infect Dis ; 23(6): 419-426, 2019.
Article in English | MEDLINE | ID: mdl-31678055

ABSTRACT

INTRODUCTION: Hepatitis B virus (HBV) is responsible for one of the most common human viral infections. An estimated 257 million people are living with chronic HBV infection worldwide, and mortality has reached 900,000 deaths in recent years. In 2001, the World Health Organization reported a prevalence of chronic hepatitis B infection in Iran between 2-7%. OBJECTIVE: To assess the effect of the national HBV mass vaccination program after 25 years. METHODS: A retrospective cohort study was conducted in vaccinated and unvaccinated people according to the year of birth. Blood samples were obtained from each enrolled person and data about demographic variables, and medical and vaccination history were collected using a standardized questionnaire. Persons were considered uninfected if they were negative for both HBsAg and anti-HBc. Also, Vaccine effectiveness was measured by calculating the risk of disease among vaccinated and unvaccinated persons and defining the percentage risk reduction of infection in the vaccinated group. RESULTS: A total of 2720 persons were interviewed. The rate of HBV breakthrough infection among the vaccinated group was significantly lower than in unvaccinated group. One hundred ninety-four cases with positive HBV markers of infection were identified. The risk ratio of HBV infection was 0.71, 95% CI: 0.54-0.94 (vaccinated/unvaccinated). The estimated vaccination effectiveness against Hepatitis B infection was 29% (95% CI: 6%-46%). CONCLUSIONS: Iran has successfully combined hepatitis B vaccination into regular immunization programs. The WHO goal of reducing HBsAg prevalence to an equivalent of 1% by 2020 has been reached. With respect to vaccination effectiveness and low prevalence of the disease in the country, catch-up hepatitis B vaccination programs for adolescents can guarantee the immunity of the population.


Subject(s)
Hepatitis B Vaccines/administration & dosage , Hepatitis B, Chronic/prevention & control , Hepatitis B/prevention & control , Immunization Programs/statistics & numerical data , Vaccination/statistics & numerical data , Adolescent , Adult , Hepatitis B/epidemiology , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/immunology , Humans , Iran/epidemiology , Male , Middle Aged , Prevalence , Retrospective Studies , Surveys and Questionnaires , Young Adult
7.
Am J Trop Med Hyg ; 101(1): 214-219, 2019 07.
Article in English | MEDLINE | ID: mdl-31115298

ABSTRACT

In 2016, the World Health Assembly endorsed the Global Health Sector Strategy on Viral Hepatitis, which calls for elimination of hepatitis B virus (HBV) by 2030 (definition: ≤ 0.1% hepatitis B surface antigen [HBsAg] prevalence among children aged 5 years). The burden of chronic HBV infection among children in Haiti is unknown. We conducted a nationally representative cross-sectional serological survey among 5- to 7-year-old children based on a two-stage cluster design with two strata: West (includes metropolitan Port-au-Prince) and non-West (all other departments). We collected demographic, socioeconomic, and vaccination history data and tested for HBsAg using a rapid point-of-care test. We estimated HBsAg prevalence and evaluated the association of HBV infection with vaccination history, demographics, and socioeconomic characteristics. Of the 1,152 children, seven (0.5%, 95% CI: 0.2-1.2) were HBsAg positive. The HBsAg prevalence varied by region (West: 0.1%, 95% CI: 0.01-0.9; non-West: 0.7%, 95% CI: 0.2-1.9) (P = 0.1), gender (males: 0.7%, 95% CI: 0.2-2.4; females: 0.2%, 95% CI: 0.05-1.1) (P = 0.3), and caregiver's education level (none: 0.8%, 95% CI: 0.2-3.1; some or completed primary: 0.5%, 95% CI: 0.1-1.8; some secondary: 0.4%, 95% CI: 0.1-1.8; secondary and higher: 0.0%, 95% CI: 0-0), although the differences were not statistically significant. None of the HBsAg-positive children had documented vaccination with hepatitis B vaccine (HepB). Haiti's chronic HBV infection prevalence among children is low; however, it is above the elimination target. To reach elimination, Haiti needs to achieve high coverage with the three HepB doses and introduce a HepB birth dose.


Subject(s)
Hepatitis B Vaccines/immunology , Hepatitis B, Chronic/epidemiology , Adult , Caregivers , Child , Child, Preschool , Cross-Sectional Studies , Female , Haiti/epidemiology , Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines/administration & dosage , Hepatitis B, Chronic/prevention & control , Humans , Male , Prevalence , Seroepidemiologic Studies , Socioeconomic Factors , Vaccination
8.
Rev Assoc Med Bras (1992) ; 64(2): 154-158, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29641674

ABSTRACT

INTRODUCTION: Hepatitis B is an important public health problem in the world and one of the forms of contagion would be through vertical transmission. Precose diagnosis allows the adoption of prophylaxis measures, which results in prevention in more than 90% of cases. OBJECTIVE: To describe the prevalences of vertical transmission and compare two generations (mother/patient and patient/child). METHOD: This was a cross-sectional study, which included 101 patients. The interviews were performed through the application of the instrument of data collection and information of the physical file before the medical consultation. RESULTS: The mean ± SD of age was 50.9 ± 13.1 years, the male gender predominated, with 56.4% of the patients, and the predominance was white, with 43.6%. Vertical transmission between mother and patient occurred in 17.8% and between patient and child, in 7.9%. In all of the eight cases of vertical transmission, the diagnosis was after the birth of children infected with HBV, and in 3/8 (37.5%), there was more than one case of infection by this mechanism per patient, totaling 13 children with the disease. CONCLUSION: There was a reduction in vertical transmission, showing that preventive measures were effective.


Subject(s)
Hepatitis B, Chronic/transmission , Infectious Disease Transmission, Vertical/statistics & numerical data , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , Brazil/ethnology , Cross-Sectional Studies , Female , Hepatitis B, Chronic/prevention & control , Humans , Infectious Disease Transmission, Vertical/prevention & control , Male , Middle Aged , Post-Exposure Prophylaxis/statistics & numerical data , Pregnancy , Prevalence , Young Adult
9.
Rev. Assoc. Med. Bras. (1992, Impr.) ; Rev. Assoc. Med. Bras. (1992, Impr.);64(2): 154-158, Feb. 2018. tab, graf
Article in English | LILACS | ID: biblio-896434

ABSTRACT

Summary Introduction: Hepatitis B is an important public health problem in the world and one of the forms of contagion would be through vertical transmission. Precose diagnosis allows the adoption of prophylaxis measures, which results in prevention in more than 90% of cases. Objective: To describe the prevalences of vertical transmission and compare two generations (mother/patient and patient/child). Method: This was a cross-sectional study, which included 101 patients. The interviews were performed through the application of the instrument of data collection and information of the physical file before the medical consultation. Results: The mean ± SD of age was 50.9 ± 13.1 years, the male gender predominated, with 56.4% of the patients, and the predominance was white, with 43.6%. Vertical transmission between mother and patient occurred in 17.8% and between patient and child, in 7.9%. In all of the eight cases of vertical transmission, the diagnosis was after the birth of children infected with HBV, and in 3/8 (37.5%), there was more than one case of infection by this mechanism per patient, totaling 13 children with the disease. Conclusion: There was a reduction in vertical transmission, showing that preventive measures were effective.


Resumo Introdução: A hepatite B é um importante problema de saúde pública no mundo e uma das formas de contágio seria através da transmissão vertical. O diagnóstico precoce possibilita a adoção de medidas de profilaxia, o que resulta na prevenção em mais de 90% dos casos. Objetivo: Descrever as prevalências de transmissão vertical e comparar duas gerações (mãe/paciente e paciente/filho). Método: Trata-se de um estudo transversal, que incluiu 101 pacientes. As entrevistas foram realizadas por meio da aplicação do instrumento de coleta de dados e informações do prontuário físico antes da consulta médica. Resultados: A média ± DP de idade foi de 50,9 ± 13,1 anos, houve predomínio do gênero masculino, com 56,4% dos pacientes, e predominou a cor branca, com 43,6%. A transmissão vertical entre mãe do paciente/paciente ocorreu em 17,8% e entre paciente/filho, em 7,9%. Em todos os oito casos de transmissão vertical, o diagnóstico foi posterior ao nascimento dos filhos infectados por HBV; em 3/8 (37,5%), houve mais de um caso de infecção por esse mecanismo por paciente, totalizando 13 filhos com a doença. Conclusão: Houve uma redução na transmissão vertical, mostrando que as medidas preventivas foram efetivas.


Subject(s)
Humans , Female , Pregnancy , Adult , Aged , Aged, 80 and over , Young Adult , Infectious Disease Transmission, Vertical/statistics & numerical data , Hepatitis B, Chronic/transmission , Brazil/ethnology , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Infectious Disease Transmission, Vertical/prevention & control , Hepatitis B, Chronic/prevention & control , Post-Exposure Prophylaxis/statistics & numerical data , Middle Aged
11.
Arch Virol ; 162(8): 2393-2396, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28439708

ABSTRACT

Thirty-two participants, aged between 3-18 years, born to hepatitis B surface antigen (HBsAg)-positive mothers and vaccinated at birth were analyzed for hepatitis B virus (HBV) infection. Overall, 56% had anti-HB titers ≥10 IU/L; five were positive for antibodies to the core antigen (anti-HBc), and two of these were also positive for HBsAg/DNA. One of the HBsAg/anti-HBc double-negative children presented with an unusual occult infection (HBV DNA-positive). No known vaccine escape mutations were detectable. Our data suggest that the vaccine protected 93.8% of children in this high-risk group against chronic HBV infection. Occult infections should be considered even in countries with low endemicity and high vaccination coverage.


Subject(s)
Hepatitis B Vaccines/immunology , Hepatitis B virus/immunology , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/epidemiology , Adolescent , Antibody Formation , Asymptomatic Infections/epidemiology , Child , Child, Preschool , Cuba/epidemiology , DNA, Viral/blood , DNA, Viral/immunology , Female , Hepatitis B Antibodies/blood , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/analysis , Hepatitis B Vaccines/administration & dosage , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/prevention & control , Humans , Male , Mothers , Pregnancy , Pregnancy Complications, Infectious , Vaccination
12.
Ann Hepatol ; 15(4): 501-11, 2016.
Article in English | MEDLINE | ID: mdl-27236149

ABSTRACT

UNLABELLED:  Introduction and aim. Studies suggest that entecavir and lamivudine are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients undergoing chemotherapy or immunosuppressive therapy, but which drug is more effective is unclear. Here we meta-analyzed available evidence on relative efficacy of prophylactic entecavir or lamivudine therapy in patients with chronic or resolved hepatitis B infection who were undergoing chemotherapy or immunosuppressive therapy. MATERIAL AND METHODS: Two reviewers searched PubMed, EMBASE and Google Scholar as well as reference lists in relevant articles to find studies published between January 2005 and May 2015 that met inclusion and exclusion criteria. Data on HBV reactivation, HBV-related hepatitis and all-cause mortality were extracted from the studies and meta-analyzed. RESULTS: A total of eight studies involving 593 patients were included in the meta-analysis, which was performed using a fixed-effect model since no significant heterogeneity was found. Entecavir was associated with significantly lower risk of HBV reactivation than lamivudine (RR 0.29, 95% CI 0.17 to 0.52) as well as lower risk of HBV-related hepatitis (RR 0.11, 95% CI 0.03 to 0.40). The two drugs were associated with similar risk of all-cause mortality (RR 1.12, 95% CI 0.54 to 2.35). Egger's test suggested no significant publication bias in the meta-analysis. CONCLUSIONS: The available evidence suggests that entecavir is more effective than lamivudine for preventing HBV reactivation and HBVrelated hepatitis in patients with chronic or resolved HBV infection who are undergoing chemotherapy or immunosuppressive therapy.


Subject(s)
Antiviral Agents/therapeutic use , Guanine/analogs & derivatives , Hepatitis B, Chronic/prevention & control , Lamivudine/therapeutic use , Virus Activation , Antineoplastic Agents/adverse effects , Disease Progression , Guanine/therapeutic use , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/etiology , Humans , Immunosuppressive Agents/adverse effects
13.
Washington D.C; s.n; 2016. 88 p. ilus, mapas.
Non-conventional in Spanish | LILACS | ID: biblio-906671

ABSTRACT

El presente informe ofrece un panorama de las epidemias actuales de hepatitis B y hepatitis C, así como de la respuesta del sector de la salud en la Región de las Américas. Su finalidad es proporcionar, en el marco de un entorno en constante cambio, un conocimiento básico de los temas principales relacionados con la respuesta a estas epidemias en la Región, para lo cual presenta un panorama de los grupos de población afectados y de la carga de las infecciones por el virus de la hepatitis B (VHB) y el virus de la hepatitis C (VHC) en la Región, además de las actuales políticas y de las prácticas del sector de la salud. Este informe, el primero en su tipo que aborda el seguimiento de los progresos en la consecución de las metas establecidas en el Plan de acción para la prevención y el control de las hepatitis virales,tiene por objeto ayudar a los Estados Miembros a adaptar sus políticas y prioridades para que puedan establecer una respuesta de salud pública eficaz e integral. Se ha producido un cambio importante en la conciencia mundial sobre las epidemias de hepatitis virales: ya no se consideran silenciosas y actualmente se observa una evolución hacia la adopción de medidas a escala mundial para eliminarlas como problema de salud pública. En la Región de las Américas, la principal carga de las hepatitis virales se debe a las hepatitis B y C; unos 2,8 millones de personas (2,2 a 8,0 millones)1presentan la infección crónica por el virus de la hepatitis B (VHB), de las cuales 2,1 millones viven...


Subject(s)
Humans , Hepatitis C/epidemiology , Immunization Programs/standards , Hepatitis B, Chronic/epidemiology , Hepatitis, Viral, Human/complications , Viral Hepatitis Vaccines/standards , Hepatitis C/prevention & control , Carcinoma, Hepatocellular/complications , Hepatitis B, Chronic/prevention & control , Health Policy , Liver Cirrhosis/complications
14.
Mem. Inst. Oswaldo Cruz ; 109(6): 728-737, 09/09/2014. tab
Article in English | LILACS | ID: lil-723991

ABSTRACT

Studies on the prevalence of infection with hepatitis B virus (HBV) among children are scarce in Latin American countries, especially in Mexico. This study was aimed to investigate the prevalence of HBV infection, occult hepatitis B infection (OBI) and HBV genotypes among children with clinical hepatitis. In total, 215 children with clinical hepatitis were evaluated for HBV infection. HBV serological markers and HBV DNA were analysed. OBI diagnosis and HBV genotyping was performed. HBV infection was found in 11.2% of children with clinical hepatitis. Among these HBV DNA positive-infected children, OBI was identified in 87.5% (n = 21/24) of the cases and 12.5% (n = 3/24) were positive for both HBV DNA and hepatitis B surface antigen. OBI was more frequent among children who had not been vaccinated against hepatitis B (p < 0.05) than in those who had been vaccinated. HBV genotype H was prevalent in 71% of the children followed by genotype G (8%) and genotype A (4%). In conclusion, OBI is common among Mexican children with clinical hepatitis and is associated with HBV genotype H. The results show the importance of the molecular diagnosis of HBV infection in Mexican paediatric patients with clinical hepatitis and emphasise the necessity of reinforcing hepatitis B vaccination in children.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Asymptomatic Infections/epidemiology , Hepatitis B virus/immunology , Hepatitis B, Chronic/epidemiology , Vaccination/methods , DNA Primers , DNA, Viral/isolation & purification , Genotype , Genotyping Techniques , Hepatitis A/diagnosis , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/classification , Hepatitis B virus/genetics , Hepatitis B, Chronic/prevention & control , Immunoglobulin M/blood , Mexico/epidemiology , Polymerase Chain Reaction , Prevalence
15.
Mem Inst Oswaldo Cruz ; 109(6): 728-37, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25099333

ABSTRACT

Studies on the prevalence of infection with hepatitis B virus (HBV) among children are scarce in Latin American countries, especially in Mexico. This study was aimed to investigate the prevalence of HBV infection, occult hepatitis B infection (OBI) and HBV genotypes among children with clinical hepatitis. In total, 215 children with clinical hepatitis were evaluated for HBV infection. HBV serological markers and HBV DNA were analysed. OBI diagnosis and HBV genotyping was performed. HBV infection was found in 11.2% of children with clinical hepatitis. Among these HBV DNA positive-infected children, OBI was identified in 87.5% (n = 21/24) of the cases and 12.5% (n = 3/24) were positive for both HBV DNA and hepatitis B surface antigen. OBI was more frequent among children who had not been vaccinated against hepatitis B (p < 0.05) than in those who had been vaccinated. HBV genotype H was prevalent in 71% of the children followed by genotype G (8%) and genotype A (4%). In conclusion, OBI is common among Mexican children with clinical hepatitis and is associated with HBV genotype H. The results show the importance of the molecular diagnosis of HBV infection in Mexican paediatric patients with clinical hepatitis and emphasise the necessity of reinforcing hepatitis B vaccination in children.


Subject(s)
Asymptomatic Infections/epidemiology , Hepatitis B virus/immunology , Hepatitis B, Chronic/epidemiology , Vaccination/methods , Adolescent , Child , Child, Preschool , DNA Primers , DNA, Viral/isolation & purification , Female , Genotype , Genotyping Techniques , Hepatitis A/diagnosis , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/classification , Hepatitis B virus/genetics , Hepatitis B, Chronic/prevention & control , Humans , Immunoglobulin M/blood , Infant , Male , Mexico/epidemiology , Polymerase Chain Reaction , Prevalence
16.
J Public Health Manag Pract ; 20(6): 662-6, 2014.
Article in English | MEDLINE | ID: mdl-24378607

ABSTRACT

OBJECTIVES: To evaluate the hepatitis B immunization status of female sex workers (FSWs) in Central-West Brazil and to evaluate their compliance with and immune response to hepatitis B vaccination delivered using outreach strategies. METHODS: A total of 721 FSWs recruited in 2 large cities in Central-West Brazil were interviewed and screened for the presence of hepatitis B virus (HBV) markers. Hepatitis B vaccine was offered to all women susceptible to HBV, using outreach strategies. The immune response of FSWs who received a full course of vaccine was assessed following the final vaccine dose. RESULTS: We found that 27.6% of FSWs, the majority of whom were aged 18 to 25 years, had serological evidence of previous hepatitis B vaccination. A total of 434 FSWs were eligible for vaccination, 389 (89.6%) of whom accepted the first hepatitis B vaccine dose. Of those, 64% received a second dose and 37.5% received all three doses. Through the outreach strategy, there was a 52.2% increase in the number of women who received the second dose and a 67% increase in the number who received the third dose. Of the 146 women who received a full course of vaccine, 105 accepted testing for quantitative anti-HBs (hepatitis B surface antibody) following the final vaccine dose, and 92.4% of those tested had developed protective levels of anti-HBs. Lower education level, workplace, and length of prostitution were predictors of full-vaccine acceptance. CONCLUSIONS: The present findings illustrate the benefits of using outreach strategies to overcome the difficulties of vaccinating hard-to-reach populations such as FSWs.


Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B Vaccines/immunology , Hepatitis B, Chronic/prevention & control , Immunization/statistics & numerical data , Patient Compliance/statistics & numerical data , Sex Workers/statistics & numerical data , Vaccination/statistics & numerical data , Adolescent , Adult , Brazil , Female , Hepatitis B/immunology , Humans , Young Adult
17.
Santiago; MINSAL; 2013. 131 p.
Non-conventional in Spanish | BIGG - GRADE guidelines, MINSALCHILE | ID: biblio-1177268

ABSTRACT

La guía está dirigida a profesionales médicos que trabajan en los Servicios de Gastroenterología y Medicina Interna tanto de niños como de adultos, de los diversos Servicios de Salud del país; médicos a cargo de los Programas de Trasplantes de Hígado y a profesionales no médicos: enfermeras o matronas que están a cargo de la atención de los pacientes con VHB y de los Programas de Trasplante; tecnólogos médicos que participan en la atención de los pacientes con VHB o están a cargo de los Servicios de Sangre.


Subject(s)
Humans , Hepatitis B virus , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/prevention & control , Hepatitis B, Chronic/virology , Carrier State , Infectious Disease Transmission, Vertical/prevention & control , Critical Pathways
18.
Rev. gastroenterol. Perú ; 31(2): 151-168, abr.-jun. 2011. tab, graf
Article in Spanish | LILACS, LIPECS | ID: lil-597277

ABSTRACT

La presente guía establece los criterios técnicos para el diagnóstico y tratamiento de la hepatitis crónica secundaria a hepatitis viral B con la finalidad de contribuir a reducir la morbimortalidad de esta enfermedad. Da las definiciones para comprender las recomendaciones aquí dadas. Descripción de aspectos epidemiológicos, factores de riesgo asociados; aspectos clínicos y de diagnóstico de la hepatitis crónica por virus B. Se dan las recomendaciones de manejo incluyendo circunstancias especiales tales como el paciente con cirrosis, el paciente con coinfección VIH ó con coinfección con hepatitis C. Las recomendaciones aquí mencionadas se convierten en la guía nacional para el manejo de la Hepatitis crónica por hepatitis B.


This guide sets out the technical criteria for the diagnosis and treatment of chronic hepatitis secondary to viral hepatitis B. The guide intend to reduce the morbidity and mortality of this disease. The Guide give practical definitions to help understand the terminology, describe epidemiology, risk factors, and clinical aspects and the diagnosis of chronic hepatitis B. Finally the guide give recommendations for the management including special circumstances such as patients with cirrhosis, patients coinfected with HIV or coinfected with hepatitis C. The recommendations of the guide become the national guide for the management of chronic hepatitis B.


Subject(s)
Humans , Male , Female , Hepatitis B, Chronic , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/prevention & control , Hepatitis B, Chronic/therapy , Hepatitis B virus
19.
Ann Hepatol ; 9(2): 120-32, 2010.
Article in English | MEDLINE | ID: mdl-20526004

ABSTRACT

Because of its frequency and grave prognosis, preventing hepatocellular carcinoma is an urgent priority. Prevention should be possible because environmental carcinogens-chronic hepatitis B and C virus infections, dietary exposure to aflatoxins, and iron overload-cause the great majority of these tumors. Chronic hepatitis B virus infection accounts for 55% of global hepatocellular carcinomas and 80% of those in the high-incidence Asia Pacific and sub-Saharan African regions. In these regions the infection that becomes chronic is predominantly acquired very early in life. A safe and effective vaccine against this virus is available and its universal inclusion in the immunization of infants has already resulted in a marked reduction of chronic infection and a 70% decrease in the occurrence of hepatocellular carcinoma in those immunized. Chronic hepatitis C virus infection is the major cause of hepatocellular carcinoma in industrialized countries. The infection is mainly acquired in adulthood and, until a vaccine becomes available, prevention will consist mainly of identifying, counselling, and treating chronically infected individuals, preventing spread of the virus by the use of safe injection practices (particularly in intravenous drug abusers), and screening all donated blood for the presence of the virus. 4.5 billion of the world.s population are exposed to dietary aflatoxins. Prevention involves treating susceptible crops to prevent fungal contamination, and handling the foodstuffs in such a way as to prevent contamination during storage. Iron overload in hereditary hemochromatosis can be prevented by repeated venesection and in African dietary iron overload by fermenting the home-brewed beer in iron-free containers.


Subject(s)
Carcinoma, Hepatocellular/prevention & control , Liver Neoplasms/prevention & control , Preventive Health Services , Aflatoxins/adverse effects , Anticarcinogenic Agents/therapeutic use , Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/etiology , Food Contamination , Hepatitis B Vaccines , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/prevention & control , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/prevention & control , Humans , Iron Overload/complications , Iron Overload/prevention & control , Liver Neoplasms/epidemiology , Liver Neoplasms/etiology , Primary Prevention , Risk Factors , Secondary Prevention
20.
Ann Hepatol ; 9(2): 166-71, 2010.
Article in English | MEDLINE | ID: mdl-20526010

ABSTRACT

BACKGROUND: Patients who receive liver transplantation for chronic hepatitis B infection require long-term combination therapy with hepatitis B immunoglobulin (HBIG) and oral antiviral medication to prophylax against graft re-infection. This study examines the efficacy and patient preference of subcutaneous (SC) administration of HBIG in maintaining anti HBs titres > 100 IU/L. MATERIALS AND METHODS: 12 patients who were stable while receiving our standard IM HBIG protocol received an alternate formulation by SC injection, consisting of 10 mL (3120 IU) HBIG as 4 x 2.5 mL SC injections. SC injection were repeated as soon as titres reached 100-150 IU/mL during the 3 month study period. A questionnaire was administered upon study entry and exit to subjectively assess patient preference. RESULTS: Anti- HBs Cmax after first injection was 441.6 IU/L +/- 81.5, and Tmax was 7.1 +/- 3.2 days. SC injections were required every 56 days, which compared well to the frequency of required IM injections prior to study enrollment of 45 days. The patients mean ratings of pain on a 0-10 scale were 5 for the IM route and 1.6 for the SC route. All patients preferred the SC injections to the IM. CONCLUSION: SC administration of HBIG can effectively maintain anti HBs levels above the requisite 100 IU/L while substantially decreasing patient discomfort and improving patient satisfaction, and therefore becomes a very attractive alternative to IM HBIG injections. Further studies and wider use of SC HBIG based on this study may alter the standard practice of transplantation centers


Subject(s)
Hepatitis B Vaccines/administration & dosage , Hepatitis B, Chronic/prevention & control , Hepatitis B, Chronic/surgery , Immunoglobulins/administration & dosage , Liver Transplantation , Adult , Aged , Antiviral Agents/therapeutic use , British Columbia , Drug Administration Schedule , Drug Therapy, Combination , Female , Hepatitis B Antibodies/blood , Hepatitis B, Chronic/complications , Humans , Injections, Intramuscular , Injections, Subcutaneous , Liver Transplantation/adverse effects , Male , Middle Aged , Patient Preference , Pilot Projects , Prospective Studies , Secondary Prevention , Surveys and Questionnaires , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL